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Primary immunodeficiencies (PIDs) refer to a clinically, immunologically, and genetically
heterogeneous group of over 350 disorders affecting development or function of the
immune system. The increasing use of next-generation sequencing (NGS) technology
has greatly facilitated identification of genetic defects in PID patients in daily clinical
practice. Several NGS approaches are available, from the unbiased whole exome
sequencing (WES) to specific gene panels. Here, we report on a 3-year experience with
clinical exome sequencing (CES) for genetic diagnosis of PIDs. We used the TruSight
One sequencing panel, which includes 4,813 disease-associated genes, in 61 unrelated
patients (pediatric and adults). The analysis was done in 2 steps: first, we focused on a
virtual PID panel and then, we expanded the analysis to the remaining genes. A molecular
diagnosis was achieved in 19 (31%) patients: 12 (20%) with mutations in genes included
in the virtual PID panel and 7 (11%) with mutations in other genes. These latter cases
provided interesting and somewhat unexpected findings that expand the clinical and
genetic spectra of PID-related disorders, and are useful to consider in the differential
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diagnosis. We also discuss 5 patients (8%) with incomplete genotypes or variants of
uncertain significance. Finally, we address the limitations of CES exemplified by 7 patients
(11%) with negative results on CES who were later diagnosed by other approaches (more
specific PID panels, WES, and comparative genomic hybridization array). In summary,
the genetic diagnosis rate using CES was 31% (including a description of 12 novel
mutations), which rose to 42% after including diagnoses achieved by later use of other
techniques. The description of patients with mutations in genes not included in the PID
classification illustrates the heterogeneity and complexity of PID-related disorders.
Keywords: primary immunodeficiencies, next generation sequencing, clinical exome sequencing, TruSight one
sequencing panel, mutations, genetic variants
INTRODUCTION
Primary immunodeficiencies (PIDs) are a phenotypically
and genetically heterogeneous group of inborn errors of
immunity leading to a predisposition to infections, autoimmune,
or autoinflammatory diseases, lymphoproliferation, and
malignancies. Typically considered as rare diseases (PID
prevalence ranges from 1:10,000 to 1:100,000 population) recent
studies indicate that they are more common than was formerly
believed (1). The diagnostic workup for PIDs has advanced from
clinical evaluation with a detailed personal and family history
to a more recent series of complex laboratory assays, including
extensive flow cytometry studies, cell culture, or western blotting.
As most described PIDs have a monogenic cause, molecular
genetic testing is usually the key to providing a definite diagnosis
(2). A positive genetic diagnosis can direct the patient toward
suitable prevention, monitoring, and treatment options. In
addition, the genetic results can help patients make choices
regarding their future, especially in terms of genetic counseling
about having children. In the case of inherited mutations, testing
of relatives is also important to expand medical care, and genetic
counseling to all affected family members and carriers. However,
achieving a definite genetic diagnosis in a suspected case of PID
can be a complex and laborious process that sometimes fails to
yield positive results.
Identification of the numerous monogenic defects underlying
PIDs has continuously increased over time. Evidence of this is
seen in the current IUIS report, which, as of February 2017,
included 354 distinct disorders with 344 different gene defects
listed (3). Remarkably, in the previous 2 years (2015–2016),
85 new causal genes were identified (4). This striking increase
in the number of disorders recognized in the last years is
undoubtedly driven by the increasingly more extensive use of
next-generation sequencing (NGS) technology. NGS has greatly
accelerated the discovery of novel disease-causing genes and
facilitated the genetic diagnosis of patients with monogenic
inborn errors of immunity (5). Several NGS approaches, ranging
from the unbiased whole exome sequencing (WES) and whole
genome sequencing (WGS) to the more restricted targeted gene
panel sequencing have been successfully used for the diagnosis
of PIDs (6). The efficacy of NGS in terms of the percentage of
positive diagnoses is difficult to establish, as it is highly dependent
of the type of PID suspected, but in general it does not reach
50% in the various cohorts reported (7–11). Several factors may
explain this relatively low percentage of success, including the
existence of complex models of inheritance (e.g., oligogenic,
polygenic, epigenetic) which are just beginning to be addressed
by the scientific community (12, 13). Moreover, the patients
included in these studies often show highly heterogeneous
PID symptoms and many are complex cases that remain
genetically unresolved after using traditional sequential Sanger
sequencing procedures. The other side of the coin of investigating
challenging patients is that novel PID-associated genes have been
discovered and unusual phenotypes caused bymutations in genes
known to cause PID have been identified (6). Hence, the use
of NGS has expanded our knowledge of the complex clinical
phenotypes associated with PID and has refined phenotype-
genotype correlations in many cases. Certain studies with more
defined cohorts in terms of PID suspicion have obtained higher
percentages of positive diagnoses. An example is the recent
study by Yu et al. focused on molecular analysis of infants
with abnormal T-cell receptor excision circles (TRECs), positive
newborn screening results, or a positive family history of PID.
Using a customized NGS-based multigene-targeted panel for
SCID and other severe PIDs, these authors identified disease-
causing mutations in 14 of 20 patients (70%) (14).
Clinical exome sequencing (CES) represents an intermediate
step between analysis by specific gene panels and WES. WES
relies on investigating all protein-coding regions of the genome
(i.e., exons+ flanking regions), and becausemost known disease-
causing mutations occur in exons, WES is considered an effective
method to identify them. However, while hundreds of genetic
conditions have been fully characterized at the clinical and
molecular level, most human genes are not actually related to
human diseases. CES focuses on known disease-associated genes
and provides a rapid and cost-effective sequencing, analysis, and
interpretation of the results.
Here, we report our experience using CES for the genetic
diagnosis of PIDs. The study included 61 children and adults,
and the molecular diagnosis was reached in 19 of them (31%).
The results are presented after dividing patients into those with
mutations in PID-causing genes (based on the IUIS classification)
and those with mutations in genes not included in the PID
classification. These latter cases have yielded interesting and
somewhat unexpected findings that expand the clinical and
genetic spectra of PID and PID-related disorders. We also discuss
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the limitations of CES, exemplified by patients with negatives
results on this test, but later diagnosed by other methods, such as
more specific PID panels, WES, and array comparative genomic
hybridization (aCGH).
MATERIALS AND METHODS
Patients and Samples
This study included 61 unrelated patients attended during a 3-
year period (2015–2017). Most patients were attended at Hospital
Universitari Vall d’Hebron (HUVH) Barcelona (Spain), but as
HUVH is a reference center for the diagnosis of PID in Spain,
samples from other regions of the country were also included.
All patients underwent a clinical history and laboratory analyses
(including immunophenotyping and functional tests), which
pointed to suspected PID. Clinical data were obtained from
the patient’s medical chart. In some patients, direct sequencing
(Sanger method) of suspected genes had been performed
previously with negative results. DNAwas isolated using different
methods, but ultimately, all samples were precipitated and
resuspended with pure water to homogenize all DNAs.
Written informed consent for the studies reported here
and for the publication was obtained from the patients or
their legal representatives, according to the procedures of the
Ethics Review Board of Hospital Universitari Vall d’Hebron
[code: PR(AG)69/2016].
Clinical Exome Sequencing and Data
Analysis
CES was carried out using the TruSight One (TSO) Sequencing
Panel (Illumina, San Diego, CA, USA) according to the
manufacturer’s instructions. The panel covers 4,813 disease-
associated genes. Targeted exonic regions underwent paired-
end sequencing on an Illumina platform using a MiSeq or
NextSeq 500 sequencing system (NextSeq High Output Kit, 300
cycles). The MSR:Enrichment v2.4.60.8 and BWA Enrichment
v2.1.1-v2.1.2 packages (BaseSpace, Illumina) were used to align
the resulting sequence reads to a reference genome (GRCh37,
hg19) (Burrows-Wheeler Aligner, BWA) and to carry out variant
calling (Genome Analysis Toolkit, GATK) (15, 16). The Isaac
Enrichment v1.0 and Enrichment v2.1.0–v3.0.0 tools were also
used for alignment and variant calling (BaseSpace, Illumina).
The sequencing quality parameters obtained from the MiSeq
sequencing platform are shown in Supplementary Table 1.
Considering the average value of a set of 20 runs with 3 samples
in each sequencing run, more than 23 million mapped reads
per run were obtained in a cluster density of 1,183 K/mm2,
with the cluster PF being 88.6%. In total, 89.7% of bases
showed a desirable quality score of ≥Q30. Two sequencing
runs of 36 samples each were performed using the NexSeq 500
platform (Supplementary Table 1). The cluster density was 151
K/mm2, the cluster PF was 86.5%, and there were 93 million
targeted reads. The percentage of bases with ≥Q30 were within
specifications in both runs, with a mean of 80.5%.
The data analysis of relevant disease variants was carried
out with the Illumina Variant Studio software v3.0 and
BaseSpaceVariant Interpreter Beta (Illumina). All variants were
TABLE 1 | Epidemiology and results summary.
Total number of patients studied 61
Female 25 (41%)
Male 36 (59%)
Mean age in years (range) 11 (0–57)
Pediatric (<18 years) 50 (82%)
Adult (>18 years) 11 (18%)
1. Patients with a genetic defect identified by CES 19 (31%)
Pediatric (% success among pediatric patients) 14 (28%)
Adult (% success among adult patients) 5 (45%)
2. Incomplete genotypes/VUS 5 (8%)
3. Patients with a genetic defect identified after CES 7 (11%)
Because gene was not included in TSO 4
Other reasons 3
4. Patients without relevant genetic findings 30 (49%)
CES, clinical exome sequencing; TSO, TruSight One Sequencing Panel; VUS, variant of
uncertain significance.
obtained using the quality parameters established by the filter
pass in the above-mentioned software. Variants considered in
this analysis were single nucleotide changes and short insertions
or deletions. PolyPhen-2 and SIFT were used to predict the
pathogenicity of the missense variants detected (17, 18). All
pathogenic variants were confirmed by Sanger sequencing.
RESULTS AND DISCUSSION
Overall Sequencing Data and Results
Summary
In this study, we report the CES results in 61 unrelated
patients with a clinically suspected PID. DNA samples were
sequenced using the TSO sequencing panel, which covers the
exons and flanking regions of 4,813 disease-associated genes.
The mean target coverage depth was 81 ± 28X, with a mean
20X target coverage of 89 ± 4% (Supplementary Table 2).
Biological data analysis involved 2 steps: First, we analyzed the
variants in a virtual PID panel of 260 genes that contained
the TSO genes included in the current IUIS classification
(Supplementary Table 3) (3), and then, we extended the analysis
to the full TSO gene panel in patients with negative results in the
virtual PID panel.
Sixty-one patients were included in the study, 36 males (59%)
and 25 females (41%), with a mean age of 11 years at enrollment
(range, 0–57 years); 82%were pediatric patients (50/61). Eighteen
percent of patients were non-Caucasian, and 23% had a family
history of consanguinity. The patients’ epidemiologic data are
summarized in Table 1. A genetic cause explaining the patient’s
phenotype was found in 31% of patients (19/61), a percentage
comparable to the rates reported in other NGS-based studies
(8–10, 19–21). Among these positive genetic results, 12 were
associated with genes included in the latest IUIS classification
(3), and 7 involved genes that are not typically associated
with classical PID phenotypes. Additionally, 5 patients showed
variants of uncertain significance (VUS) or incomplete genotypes
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in genes related to their clinical phenotype. Of the 39 patients
without a positive genetic diagnosis by CES, 7 (11%) were
successfully diagnosed later using other approaches. CES had
failed for the following reasons: (1) the genes were not included
in the CES panel, (2) large genomic rearrangements were not
successfully detected by CES, and (3) mutations occurred in
non-coding regions, which are beyond the scope of CES. In
the following sections, these results are described in detail
and discussed. The clinical and laboratory data of the patients
included in the next sections are summarized in Tables 2, 3. The
clinical and laboratory data of all patients (n = 61) included in
the study are summarized in Supplementary Tables 4, 5.
Patients With Mutations in PID Genes (2017
IUIS Classification)
The filtering strategy for PID genes included in the current IUIS
classification led to a molecular diagnosis in 12 cases (Table 4).
Mean age in this group was 14.8 years (range, 1–57), and the
male-to-female ratio was 1.4.
Three patients (P1, P2, and P3) had mutations in genes
predominantly causing antibody deficiencies.
P1 is a 15-year-old male referred to our center at the age of 4
due to recurrent viral infections (rubella, EBV, cytomegalovirus),
growth delay, lymphadenopathies, and chronic ear infections.
The patient further developed a large bowel lymphoma, and
presented an ALPS-like phenotype. Previous Sanger sequencing
studies of the FAS and XIAP genes were negative. CES revealed
a heterozygous mutation in the PIK3R1 gene, responsible for
activated PI3K delta syndrome type 2 (APDS2). The mutation,
c.1425+1G>A, is the one most often described in this syndrome
(22, 23). Identification of this mutation allowed the patient to
enter a clinical trial for a selective PI3K delta inhibitor, but he had
to discontinue after several weeks due to severe adverse effects.
Unfortunately, he ultimately died at the age of 18 years.
Patients P2 and P3 had common variable immune deficiency
(CVID)-like antibody deficiencies. P2 is a 57-year-old woman
who reported recurrent upper respiratory tract infections
since the age of 14 years, which continued despite intravenous
immunoglobulin (IVIG) treatment. She also experienced
acute diarrhea due to Aeromonas Hydrophila, granulomatous
lymphadenopathies, hepatosplenomegaly, long periods of fever
with elevated acute phase reactants, hypogammaglobulinemia,
central pancytopenia, and granulomatous-lymphocytic
interstitial lung disease (GLILD). P3 showed the first symptoms
at the age of 3. She had episodes of EBV infection, autoimmune
pancytopenia, hypogammaglobulinemia, pathological axillary
lymphadenopathies, and hepatosplenomegaly. Previous genetic
studies ruled out FAS and PIK3R1mutations. In both patients,
heterozygous mutations were found in TNFRSF13B (the gene
that codes for TACI). P2 had one of the most common missense
mutations associated with CVID, c.310T>C/p.Cys104Arg
(24, 25), and P3 had the c.260T>A/p.Ile87Asn mutation (26, 27).
It has been demonstrated that both these mutations impair
the capacity of TACI ligation to activate the NFκB pathway
(27). TACI mutations are not considered to be fully-penetrant
causal mutations, as most carriers show no disease, but up to
10% of CVID patients bear a mutation in TACI (compared to
approximately 1% of the healthy population), which supports
a role of TACI mutations in CVID or CVID-like disorders.
Therefore, in P2 and P3 heterozygous TACI mutations cannot
be considered causal by itself, but a predisposing factor in
combination with other genetic and/or environmental factors.
P4 is an 18-year-old male who, since the age of 14,
had experienced severe Crohn’s-like gut inflammation and
arthritis. He had a maternal family history of autoimmunity,
and Crohn’s disease on the paternal side. Mutations in XIAP
and FOXP3 had been ruled out prior to this study. CES
revealed a hemizygous missense mutation in IKBKG (the
gene that codes for NEMO), c.169G>A/p.Glu57Lys. IKBKG
hypomorphic mutations, which reduce but do not abolish
NF-κB activation, have been identified in male patients with
a spectrum of X-linked clinical phenotypes, ranging from
anhidrotic ectodermal dysplasia (EDA) with immunodeficiency
(EDA-ID) to immunodeficiency without EDA. IKBKG loss-of-
function mutations are lethal in males and cause incontinentia
pigmenti (IP) in females (39). Our patient did not have
EDA and the main clinical manifestation was gastrointestinal
inflammation. He did not show hypogammaglobulinemia or
relevant infections, 2 clinical features usually seen in typical EDA-
ID patients (39). The IKBKG p.Glu57Lys mutation has been
previously described in 2 unrelated patients, 1 with EDA-ID
(40), and 1 with immunodeficiency without EDA (28). The latter
study demonstrated that IKBKG p.Glu57Lys leads to specific
immunological defects in vitro (28). Interestingly, this mutation
has also been associated with a mild form of IP (29, 41). Given the
relatively high frequency of p.Glu57Lys in the general population
(MAF= 0.001), this mutation if pathogenic should be considered
to have low penetrance.
P5 is 10-year-old girl who experienced recurrent atypical
mycobacterial infections mainly in skin and gut since the age
of 4. She also had hypertelorism, craniosynostosis, and scoliosis.
Low Th17 cell counts and increased IgE levels pointed to
mutations in genes responsible for hyper IgE syndrome, and
indeed, CES revealed a heterozygousmissensemutation in STAT3
(c.1144C>T/p.Arg382Trp). This mutation, located in the DNA-
binding domain of the protein, is one of the most frequent
STAT3-dominant negative mutations described (30, 31).
P6, a 2-year-old boy born of consanguineous parents,
presented with enteropathy, bacterial infections, and growth
delay at the age of 10 months. Based on a strong suspicion
of PID, the attending pediatricians sent us a sample for
inclusion in our genetic study, with no previous laboratory
determinations. We found a novel hemizygous truncating
mutation in XIAP (c.888_892del/p.Lys299LeufsX9), causing type
2 X-linked proliferation syndrome (XLP-2) (42), which perfectly
fit the patient’s clinical phenotype.
P7 is a boy referred to our hospital at the age of 4 months
due to severe osteomyelitis caused by Salmonella spp. Functional
tests revealed a normal respiratory burst test, but in vitro IFNγ
and IL-12 production was impaired. Surprisingly, CES revealed
a hemizygous mutation in G6PD, c.934G>C/p.Asp312His,
reported to be responsible for class III G6PD deficiency.
G6PD deficiency is the most common genetic cause of chronic
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TABLE 2 | Main clinical features of patients with relevant genetic findings.
ID Sex Age at
study (y)
Gene Family
history
Consanguinity Age of
onset (y)
Syndromic
features
Infections Autoimmunity Lymphoproliferation Inflammation Main clinical features, key
words
Treatment
PATIENTS WITH MUTATIONS IN PID GENES (2017 IUIS CLASSIFICATION)
P1 M 15 PIK3R1 – – 7 – V – Malign Gut IgA deficiency, immune
dysregulation, growth delay,
enteropathy, intestinal large bowel
lymphoma
IVIG, immunosuppression
(rapamycin and rituximab)
P2 F 57 TNFRSF13B – – 14 – B – Benign Gut, lung CVID, infections, GLILD,
granulomas, adenopathies,
pancytopenia
IVIG, immunosuppression
(rituximab, corticoids,
azathioprine), antibiotics
P3 F 8 TNFRSF13B
√
– 3 – B, V
√
Benign – EBV, pancytopenia,
hepatosplenomegaly,
hypogammaglobulinemia,
ALPS-like, CVID-like
IVIG, rapamycin
P4 M 18 IKBKG
√
– 14 – – – – Gut, joints Crohn’s disease, joint affectation,
CGD, NEMO deficiency
Infliximab
P5 F 10 STAT3 – – 4
√
B, F, Myc – – – Hyper IgE, atypical mycobacteria Antifungal prophylaxis, vitamin
D, IVIG, antibiotics
P6 M 2 XIAP –
√
0.8
√
B – – Gut Enteropathy, bacterial infection,
growth delay
IVIG, patient died
P7 M 1 G6PD – – 0.3 – B – – Bone Osteomyelitis, Salmonella spp. -
P8 M 30 STAT1 – – 0.0 – F
√
– Skin, mucosa Dermatophytosis, oral candidiasis Antifungal prophylaxis,
P9 F 4 STAT1 – – 0.8 – F – – Joints CMC, polyarthritis, episcleritis,
bronchiectasis
Ruxolitinib, HSCT
P10 M 6 STAT1
√ √
4 – F – – – Familial CMC Antifungal prophylaxis
P11 F 12 PLCG2 – – 0.8
√
B – – Skin, lungs Agammaglobulinemia, severe
cutaneous inflammation,
bronchiectasis, B cell lymphopenia,
growth delay
IVIG, antibiotics, corticosteroids,
etanercept, anakinra
P12 M 15 ADA – – 8 – B – Malign – Hodgkin lymphoma, B cell
deficiency
Chemotherapy
PATIENTS WITH MUTATIONS IN GENES NOT INCLUDED IN THE PID CLASSIFICATION
P13 M 5 SKIV2L – – 0.8
√
B – – Gut Inflammatory enteropathy, growth
delay
Antibiotics, IVIG, adalimumab,
immunosuppression
(azathioprine, prednisone,
rapamycin)
P14 M 0.25 MMACHC
√
– 0.1 – – – – – fHLH, XLP Died before diagnosis
P15 F 44 SLC27A4 –
√
n.a. – – – – Skin Netherton syndrome -
P16 F 0.3 DSG1 – – 0.3 – B – – – Erythroderma, Netherton syndrome,
hyper IgE, eosinophilia
Infliximab, adalimumab,
cyclosporine
P17 F 1 DNAI2
√ √
0.1 – V, F
√
Malign – Recurrent bronchitis, biphenotypic
leukemia, growth delay
HSCT (due to leukemia)
P18 M 38 SIX6
√ √
n.a. – B – – – CID, Low IgA IVIG
P19 M 5 RECQL4 –
√
1
√
V, F – – – CVID, growth delay IVIG, antibiotic prophylaxis
(Continued)
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TABLE 2 | Continued
ID Sex Age at
study (y)
Gene Family
history
Consanguinity Age of
onset (y)
Syndromic
features
Infections Autoimmunity Lymphoproliferation Inflammation Main clinical features, key
words
Treatment
PATIENTS WITH INCOMPLETE GENOTYPES/VARIANTS OF UNCERTAIN SIGNIFICATE (VUS)
P20 M 11 UNC13D
√
– 8 – V – Malign Gut Pancytopenia,
hepatosplenomegaly,
hemophagocytosis, panniculitic T
cell lymphoma
HSCT (due to T cell lymphoma)
P21 M 13 RAG2
√
– 6
√
– – Benign Systemic Persistent fever, intermittent
abdominal pain, granulomatous
hepatitis
Immunosuppression
(methotrexate + colchicine +
corticosteroids)
P22 M 4 PLCG2
√ √
1 – V – – Skin Periodic fever, skin rash -
P23 F 11 TRAF3 – – 11 – V – – – Herpes Zoster, VZV
meningoencephalitis
-
P24 M 2 NOD2 – – 0.6 – – – – Gut Early-onset colitis -
PATIENTS WITH GENETIC FINDINGS POST-CLINICAL EXOME
P25 F 8 LRBA
√
– 0.7 – B, V, F
√
Malign Gut EBV, lymphoproliferation,
autoimmunity, infections,
dysregulation, enteropathy,
autoimmune cytopenia
IVIG, rapamycin, antibiotic
prophylaxis, HSCT
P26 F 11 LRBA – – 2 – V
√
Benign – ALPS IVIG, abatacept
P27 F 7 LRBA – – 7 – B
√
Benign – Antibody deficiency, autoimmunity,
lymphoproliferative syndrome
IVIG, abatacept
P28 F 14 IKZF1
√
– 5
√
B – – – Agammaglobulinemia, neurological
delay
IVIG
P29 M 9 13Mb del cr.6
√ √
0.0
√
B, V – – – Neutrophilic dermatosis, oral and
genital aphthae, growth delay
Etanercept
P30 M 6 BTK – – 4 – B – – – Pneumonia,
hypogammaglobulinemia, absence
of B cells
IVIG
P31 M 25 Gorham-
Staut
disease
– – 21
√
B – – Joints Osteopenia, chylothorax,
lymphopenia, S.Aureus bacteremia,
septic arthritis
-
n.a., not available; –, no; V, virus; B, bacteria; F, fungi; Myc, mycobacteria; ALPS, autoimmune lymphoproliferative syndrome; CID, combined immunodeficiency; CGD, chronic granulomatous disease; CMC, chronic mucocutaneous
candidiasis; CVID, common variable immunodeficiency; EBV, Epstein-Barr virus; fHLH, familial hemophagocytic lymphohistiocytosis; GLILD, granulomatous and lymphocytic interstitial lung disease; HSCT, hematopoietic stem cell
transplant; IVIG, intravenous immunoglobulin; VZV, varicella-zoster virus; XLP, X-linked lymphoproliferation.
√
, The patient presents this feature.
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TABLE 3 | Laboratory data of patients with relevant genetic findings.
ID Sex Age at
study (y)
Gene Hypogammaglobulinemia Neutropenia Lymphopenia Thrombocytopenia Immunophenotype Functional tests
PATIENTS WITH MUTATIONS IN PID GENES (2017 IUIS CLASSIFICATION)
P1 M 15 PIK3R1 – – – – Inverse CD4/CD8. No switched
memory B cells
Low proliferation with anti-CD3,
altered in vivo response to
Haemophilus influenzae
P2 F 57 TNFRSF13B
√ √ √ √
Low CD4 naïve T cells, low Tregs,
low pre-switched and switched B
cells
n.a.
P3 F 8 TNFRSF13B
√ √ √ √
Low CD4 naïve T cells, low
pre-switched and switched B cells
Normal proliferation, cytotoxicity
and degranulation
P4 M 18 IKBKG – – – – Increased DN gamma delta T cells
(22%)
Normal respiratory burst test and
cytotoxicity/degranulation assays
P5 F 10 STAT3 – – – – Low Tregs, low Th17 Very low proliferation with
anti-CD3
P6 M 2 XIAP – – – – n.a. n.a.
P7 M 1 G6PD – – – – Inverse CD4/CD8 ratio. Increased
effector HLA-DR+ CD8+ T cells,
low switched B cells
Very low proliferation with
anti-CD3 and ConA, very low
IFNγ and IL12 production
P8 M 30 STAT1 – – – – Myeloid DC >>> plasmacytoid
DC
Negative in vivo response to
Candidin.
P9 F 4 STAT1 – – – – Low CD4 naïve T cells, low Th17,
low pre-switched B cells
Low proliferation with PHA
P10 M 6 STAT1 – – – – 3.4% DN TCR αβ T cells, increased
Th1, low Th17, low Tregs
Low IL12 and IFNγ production
P11 F 12 PLCG2 – – – – T+ B- NK+ Normal proliferation, normal
respiratory burst test
P12 M 15 ADA
√
– – – T+ B- NK- Normal respiratory burst test
PATIENTS WITH MUTATIONS IN GENES NOT INCLUDED IN THE PID CLASSIFICATION
P13 M 5 SKIV2L
√
– – – Normal Low proliferation with PHA
(normal to anti-CD3 and ConA),
normal respiratory burst test
P14 M 0.25 MMACHC –
√
–
√
n.a. Absent degranulation and
cytotoxicity
P15 F 44 SLC27A4 – – – – Normal Normal
P16 F 0.3 DSG1 – – – – Very low effector and memory T
cells, low Th2, low Th1/Th17
n.a.
P17 F 1 DNAI2 – – – – Normal Low proliferation with PWM and
PHA
P18 M 38 SIX6 – – –
√
Low switched memory B cells Low proliferation with anti-CD3
P19 M 5 RECQL4
√
–
√ √
Increased CD4/CD8 ration Low proliferation with PWM,
anti-CD3, and ConA.
(Continued)
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TABLE 3 | Continued
ID Sex Age at
study (y)
Gene Hypogammaglobulinemia Neutropenia Lymphopenia Thrombocytopenia Immunophenotype Functional tests
PATIENTS WITH INCOMPLETE GENOTYPES/VARIANTS OF UNCERTAIN SIGNIFICANCE (VUS)
P20 M 11 UNC13D –
√ √
– Normal Alternate low/normal
degranulation and cytotoxicity
P21 M 13 RAG2 – –
√ √
Low T cells, low NK cells. Normal proliferation, normal
respiratory burst test
P22 M 4 PLCG2 –
√
– – Normal n.a.
P23 F 11 TRAF3 – – – – Normal Absent IL-12 production, normal
IFNγ production
P24 M 2.0 NOD2 – – – – Normal Normal proliferation, normal
respiratory burst test
PATIENTS WITH GENETIC FINDINGS POST-CLINICAL EXOME
P25 F 8 LRBA
√ √ √
– T+ B- NK- Low/absent degranulation and
cytotoxicity
P26 F 11 LRBA – – – – 4.2% DN TCR αβ T cells, low
effector and memory T cells, low
Tregs
Low CD69 and CD40L expression
P27 F 7 LRBA
√
– – – Low pre-switched and switched B
cells
Low pneumococcal response
P28 F 14 IKZF1
√
– – – T+ B- NK+, low pre-switched and
switched B cells
Negative ASLO
P29 M 9 13Mb del
cr.6
– – – – Normal Low proliferation with anti-CD3,
normal TNFα production in
response to LPS, normal
degranulation and cytotoxicity
P30 M 6 BTK
√
– – – T+ B- NK+ n.a.
P31 M 25 Gorham-
Staut
disease
–
√
– – Low CD4T cells, increased NK
cells
Severe defect in IL12 production,
altered respiratory burst test
n.a., not available; -, no; ASLO, anti-streptolysin O; ConA, concanavalin A; DC, dendritic cell; DN, double negative; PHA, phytohemagglutinin; PMA, phorbol 12-myristate 13-acetate; PWM, pokeweed mitogen.
√
, The patient presents
this feature.
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TABLE 4 | Relevant genetic findings in patients included in this study.
Patient Gene Chr OMIM cDNA Protein Consequence Zygosity Inheritance dbSNP ID ExAc
MAF
PolyPhen2 SIFT Previous report
of variant
MUTATIONS IN PID GENES (2017 IUIS CLASSIFICATION)
P1 PIK3R1 5 616005 c.1425+1G>A Splicing defect Heterozygous AD rs587777709 (22, 23)
P2 TNFRSF13B 17 240500 c.310T>C p.Cys104Arg Missense Heterozygous AR, AD rs34557412 0.003212 Deleterious (0) probably damaging (1) (24, 25)
P3 TNFRSF13B 17 240500 c.260T>A p.Ile87Asn Missense Heterozygous AR, AD rs72553877 0.000461 Deleterious (0) probably_damaging (0.924) (26, 27)
P4 IKBKG X 300291 c.169G>A p.Glu57Lys Missense Hemizygous X-linked rs148695964 0.001190 Deleterious
(0.01)
probably_damaging (0.995) (28, 29)
P5 STAT3 17 147060 c.1144C>T p.Arg382Trp Missense Heterozygous AD rs113994135 Deleterious (0) probably_damaging (0.999) (30, 31)
P6 XIAP X 300635 c.888_892del p.Lys299LeufsX9 Frameshift Hemizygous X-linked Novel
P7 G6PD X 300908 c.934G>C p.Asp312His Missense Hemizygous X-linked rs137852318 0.000840 Deleterious (0) probably_damaging (0.911) (32)
P8 STAT1 2 614162 c.1060C>G p.Leu354Val Missense Heterozygous AD Tolerated (0.19) benign (0.363) Novel
P9 STAT1 2 614162 c.1030A>G p.Lys344Glu Missense Heterozygous AD Deleterious (0) probably_damaging (0.977) Novel
P10 STAT1 2 614162 c.397A>G p.Thr133Ala Missense Heterozygous AD rs1397948697 Tolerated (0.8) benign (0.002) Novel
P11 PLCG2 16 614878 c.2534_2545del p.Leu845_Leu848del In frame
deletion
Heterozygous AD Novel
P12 ADA 20 102700 c.320T>C p.Leu107Pro Missense Compound Het AR rs121908739 0.000074 Deleterious (0) probably_damaging (0.999) (33)
P12 ADA 20 102700 c.1A>G p.Met1Val Start loss Compound Het AR rs1363043396 Novel
MUTATIONS IN GENES NOT INCLUDED IN THE PID CLASSIFICATION (UNEXPECTED FINDINGS)
P13 SKIV2L 6 614602 c.2203-1G>A Splicing defect Compound Het AR rs144714933 0.000008 (34)
P13 SKIV2L 6 614602 c.3187C>T p.Arg1063X Stop gained Compound Het AR rs138923214 0.000129 (35, 36)
P14 MMACHC 1 277400 c.271dupA p.Arg91LysfsX14 Frameshift Homozygous AR (37)
P15 SLC27A4 9 608649 c.1320_1321insCp.Gly442ArgfsX2 Frameshift Homozygous AR Novel
P16 DSG1 18 615508 c.1A>G p.Met1Val Start loss Compound Het AR rs1388337318 Novel
P16 DSG1 18 615508 c.2569C>T p.Arg857X Non-sense Compound Het AR rs756245217 Novel
P17 DNAI2 17 612444 c.546C>A p.Tyr182X Non-sense Homozygous AR rs770946088 Novel
P18 SIX6 14 212550 c.86G>C p.Arg29Pro Missense Homozygous AR Deleterious
(0.02)
Benign (0.387) Novel
P19 RECQL4 8 268400 c.2789_2812del p.His930_Leu937del In frame
deletion
Homozygous AR Novel
INCOMPLETE GENOTYPES/VARIANTS OF UNCERTAIN SIGNIFICANCE (VUS)
P20 UNC13D 17 608898 c.3224G>A p.Arg1075Gln Missense Heterozygous AR rs377594755 0.000197 Deleterious
(0.01)
Possibly_damaging (0.892) Novel
P21 RAG2 11 603554 c.1324G>A p.Ala442Thr Missense Heterozygous AR rs763513886 0.000008 Deleterious (0) Probably_damaging (0.998) Novel
P22 PLCG2 16 614878 c.2393A>G p.Asn798Ser Missense Heterozygous AD rs117077093 0.000676 Deleterious
(0.05)
Probably_damaging (0.998) Novel
P23 TRAF3 14 614849 c.718G>A p.Val240Ile Missense Heterozygous AD rs200118821 0.000082 Tolerated (0.15) Benign (0.01) Novel
P24 NOD2 16 266600 c.2753C>A p.Ala918Asp Missense Heterozygous AR, AD rs104895452 0.000395 Deleterious (0) Probably_damaging (0.997) (38)
AD, autosomal dominant; AR, autosomal recessive; Chr, chromosome; IUIS, international union of immunological societies; MAF, minor allele frequency; SIFT, sorting intolerant from tolerant.
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hemolytic anemia (43). To date, nearly 200G6PDmutations have
been identified (44, 45), all of them causing a more or less marked
G6PD deficiency, but preserving some residual G6PD activity in
red cells (complete absence of G6PD activity would be lethal)
(43). In the original descriptions, eachG6PD variant was assigned
to a class defined on the basis of residual enzymatic activity and
clinical manifestations. The p.Asp312His mutation, also known
as the Seattle-like variant, is a class III variant in which enzymatic
activity is about 15% of normal (activity associated with class
III ranges from 10 to 60% of normal activity) (46). Our patient
did not have anemia or other cytopenias, although he showed
reduced G6PD activity in red cells. Therefore, he was currently
asymptomatic in terms of hemolytic anemia, which is not
surprising as class III variants are considered to have incomplete
penetrance (47). Furthermore, although severe G6PD deficiency
can be a phenocopy of chronic granulomatous disease (48), that
would not be the case of the p.Asp312His mutation associated
with a mild form of G6PD deficiency. As was mentioned, our
patient had a normal respiratory burst test and G6PD activity
in granulocytes was within the normal range. In summary, this
patient has a G6PD mutation that does not fully explain the
clinical phenotype, and he remains under study.
In patients P8, P9 and P10, all showing a predominant clinical
phenotype of chronic fungal infections since early ages, we
found heterozygous mutations in STAT1. Heterozygous gain-
of-function (GOF) mutations in STAT1 are the most common
genetic cause of chronic mucocutaneous candidiasis (CMC)
(49, 50). Almost all reported patients present with fungal
infections (mainly candida), but also with a wide range of
other clinical features, including bacterial infections primarily
affecting the respiratory tract (51). The STAT1 mutations in
P8 (c.1060C>G/p.Leu354Val) and P9 (c.1030A>G/p.Lys344Glu)
were novel and had occurred de novo in the patients. Both
mutations are located in the DNA-binding domain of the
protein, which, together with the coiled-coil domain (CCD),
are the 2 main STAT1 domains where GOF mutations are
located (49, 51). A mutation affecting the same residue of
STAT1 (p.Leu354Met) as in P8 has been described in a
patient with CMC (51). Patient P10 also showed a novel
STAT1 mutation (c.397A>G/p.Thr133Ala) inherited from his
asymptomatic mother. The Thr133Ala variant is located outside
of, but very close to the CCD, which spans residues 136 to 317.
The patient has 2 siblings who are also carriers of the mutation
and who have also had CMC episodes since an early age. The
CMC episodes of all 3 affected children resolved with the oral
antifungal fluconazole, and all of them remain symptom-free
to date.
P11 is a 12-year old girl with very early-onset severe skin
and eye inflammation and recurrent respiratory infections
(due to profound hypogammaglobulinemia), leading to the
development of multiple bronchiectasis. CES revealed a
novel, de novo heterozygous mutation in PLCG2, consisting
of a 12-bp in-frame deletion in exon 24, leading to the loss
of 4 amino acids (c.2534_2545del/p.Leu845_Leu848del).
The deletion was located in the protein region encoding
autoinhibitory domains. Heterozygous GOF mutations affecting
the autoinhibitory domains of PLCG2 have been associated with
2 different syndromes: PLAID (phospholipase Cγ2-associated
antibody deficiency and immune dysregulation) and APLAID
(autoinflammation and phospholipase Cγ2-associated antibody
deficiency and immune dysregulation) (52, 53). Both syndromes
are autoinflammatory-related disorders that typically show
sinopulmonary infections caused by a humoral defect. The
main difference between them is that APLAID patients do
not have cold-induced urticaria, as occurs in patients with
PLAID syndrome (54). The 2 phenotypes seem to be related
to the type of mutation: PLAID is a consequence of large
genomic PLCG2 deletions (52), and the only 2 families reported
with APLAID carried missense mutations (S707Y and L848P)
(53, 55). However, since very few families with PLAID or
APLAID have been described so far, this distinction must be
considered with caution. In fact, P11 had a clinical phenotype
compatible with APLAID syndrome, whereas the mutation
was a small in-frame deletion, a type of mutation that has not
yet been reported in APLAID. Immunological and functional
studies are being conducted to investigate the pathogenicity
of the PLCG2 p.Leu845_Leu848del mutation and determine
the functional abnormalities related with activation of the
NLRP3 inflammasome.
P12 is a 15-year old boy who presented with Hodgkin
lymphoma and hypogammaglobulinemia (with low B and NK
cell counts) at the age of 8 years. He experienced recurrent
bacterial respiratory tract infections, including pneumonia. At
the time of the Hodgkin lymphoma diagnosis, concomitant EBV
infection was detected. This led us to perform direct sequencing
of the SH2D1A (SAP), XIAP, and PIK3R1 genes, with negative
results. CES revealed a compound heterozygous mutation in the
ADA gene, consisting of a previously reported missense mutation
(c.320T>C/p.Leu107Pro) and a novel mutation affecting the
start codon (c.1A>G/p.Met1Val). It has been demonstrated
that p.Leu107Pro is a loss-of-function mutation that retains
<0.01% of wild-type activity (56). Complete ADA deficiency
is a well-known cause of severe combined immunodeficiency
(SCID) but, clearly, our patient did not have a SCID phenotype.
Hypomorphic mutations in the ADA gene can lead to a different
immunodeficiency with a variable phenotype including signs
of immune dysregulation (56, 57). As our patient fit in the
category of late-onset ADA deficiency, we hypothesize that the
novel p.Met1Val is a hypomorphic mutation allowing some ADA
activity and thereby, rescuing our patient from a more severe
phenotype (the functional effect of the p.Met1Val mutation is
under study).
Patients With Mutations in Genes Not
Included in the PID Classification:
Unexpected Findings
After the first step in the analytical strategy, focused on PID
genes included in the IUIS classification, all patients with
negative findings underwent a second analysis including the
remaining genes of the clinical exome. Seven additional patients
were diagnosed in this second analysis. As all patients were
included in this study based on a suspicion of PID, most of the
following findings were unexpected and interesting to consider
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in the differential diagnosis of suspected PID. The clinical and
laboratory data of all patients described are summarized in
Tables 3, 4.
SKIV2L—Trichohepatoenteric Syndrome 2 (OMIM
#614602)
P13 is a 5-year-old boy who presented with acute gastroenteritis,
Enterococcus faecalis bacteremia, and dehydration at the age
of 8 months. Thereafter, he had episodes of viral disease
that severely affected his enteropathy. He also experienced
catheter-associated bacteremia caused by Staphylococcus
epidermidis. The patient had short stature and psychomotor
delay. Immunological laboratory tests disclosed profound
hypogammaglobulinemia, absence of a vaccine response,
and low lymphocyte proliferation after PHA stimulation.
Based on these findings, IVIG treatment was initiated. The
immunodysregulation polyendocrinopathy enteropathy X-
linked (IPEX) syndrome was initially suspected, but direct
sequencing of FOXP3 showed no mutations. A second CES
analysis revealed a compound heterozygous mutation in SKIV2L,
consisting of one mutation affecting the intron 18 consensus
acceptor splice site (c.2203-1G>A) and another introducing a
premature stop codon in exon 26 (c.3187C>T/p.Arg1063X).
The parents were heterozygous carriers. Both these mutations
have been recently reported in several patients (34–36).
Homozygous or compound heterozygous mutations in SKIV2L
lead to type-2 trichohepatoenteric syndrome (THES2), first
described in 2012 as a rare congenital bowel disorder mainly
characterized by intractable diarrhea (58). Fewer than 40 patients
have been reported so far with this condition [excellently
reviewed in Bourgeois et al. (36)], which is characterized by
9 main clinical signs: intractable diarrhea, hair abnormalities,
facial dysmorphism, intrauterine growth restriction (IUGR),
immunodeficiency, skin abnormalities, liver disease, congenital
heart defects, and platelet anomalies. Accordingly, our patient
presented a similar phenotype with low stature, neonatal
enteropathy, absence of a vaccination response, intellectual
disability, and extraordinarily brittle hair.
Generically, trichohepatoenteric syndrome can be caused
by mutations in either SKIV2L (THES2) or TTC37 (THES1),
with very similar clinical manifestations (although patients with
SKIV2L mutations seem more severely affected than those with
TTC37). Whereas, TTC37 deficiency is included in the IUIS
classification of PIDs in the category of predominantly antibody
deficiencies (59), SKIV2L deficiency is not present. We propose
that SKIVL2 deficiency be included in the next IUIS classification.
The above-mentioned features and the defects in the B and
T cell compartments seen in our patient and other reported
THE patients (60), indicate that both TTC37 and SKIV2L
deficiency should be included in the category of combined
immunodeficiencies with associated or syndromic features.
MMACHC—Methylmalonic Aciduria and
Homocystinuria (OMIM #277400)
P14 had a family history of an older brother who died at
the age of 4 months with a diagnosis of hemophagocytic
lymphohistiocytosis (HLH) and pancytopenia. Hence, when
he was referred to our center at the age of 1 month
with a clinical phenotype of pancytopenia, bone marrow
hemophagocytosis, and increased ferritin levels, familial HLH
and X-linked lymphoproliferative syndrome (XLP-1, XLP-2)
were both suspected. The patient showed no cytotoxicity or
degranulation, and perforin expression was normal on flow
cytometry. Following CES, we carefully analyzed genes related
with HLH and XLP (PRF1, UNC13D, STX11, STXBP2, SH2D1A,
XIAP), but no mutations were found. Other genes in the
virtual PID panel were also normal. Finally, in the overall CES
analysis, a homozygous insertion was detected in one nucleotide
of the MMACHC gene (c.271dupA), leading to a truncated
protein (p.Arg91LysfsX14). The non-consanguineous parents
were heterozygous carriers. Biallelic mutations in MMACHC
cause a disease referred to as methylmalonic aciduria and
homocystinuria, which is a genetically heterogeneous disorder
of cobalamin (vitamin B12) metabolism (61). Two distinct
phenotypes of MMACHC (cobalamin C) deficiency have been
defined in terms of age of onset. Early-onset patients present
in the first year of life with non-specific systemic, neurological,
and hematological abnormalities, and have a poor outcome.
Late-onset patients usually show acute neurological deterioration
after the age of 4 years, with a better outcome after treatment
(62, 63). Our patient clearly fit in the early-onset group, which is
concordant with his genotype, as c.271dupA is the most common
related mutation in Europeans and is associated with severe
early-onset disease (37, 64).
Although uncommon, HLH can be the initial presentation of
MMACHC deficiency. Wu and collaborators reported on a 4-
month-old patient initially diagnosed with HLH, who was later
diagnosed with cobalamin C disease (cblC) (65). Therefore, early-
onset cblC should be considered in the differential diagnosis of a
patient with a clinical presentation of very early-onset infantile
HLH. Our patient ultimately died despite the start of intravenous
of vitamin B12 treatment. Tandem mass spectrometry-based
newborn screening should include the detection of congenital
cobalamin defects, including MMACHC deficiency, to allow the
early diagnosis prior to the onset of symptoms.
SLC27A4—Ichthyosis Prematurity Syndrome (OMIM
#608649)
P15 is a 44-year-old woman from a consanguineous family.
She was referred to the Dermatology Department due to
excessive skin inflammation since infancy. Dermatological
findings lead to a suspicion of Netherton syndrome, an autosomal
recessive disease caused by mutations in the SPINK5 gene
and characterized by congenital ichthyosis, bamboo hair, and
atopic diathesis. Although mainly a skin disorder, Netherton
syndrome was defined as a PID in 2009, when the group of
Professor H. Ochs evaluated the immune system in a cohort of
Netherton patients and found that almost all had reductions in
memory B cell counts, a defective vaccine response, increased
inflammatory cytokines, and lowNK cytotoxicity (66). The initial
CES analysis focused on the SPINK5 gene, which was found to
be completely normal. The differential diagnosis of Netherton
syndrome includes genes causing inherited ichthyoses, PIDs
with hyper IgE, atopic dermatitis, and seborrheic dermatitis,
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among other conditions (67, 68). The virtual PID panel
analysis was negative, but analysis of the other related genes
identified a homozygous truncating mutation in the SLC27A4
gene (c.1320_1321insC/p.Gly442ArgfsX2). Biallelic mutations in
SLC27A4 (mainly known as FATP4) cause ichthyosis prematurity
syndrome (IPS), an autosomal recessive disorder characterized
by premature birth and neonatal respiratory complications,
followed by lifelong ichthyosis with atopic manifestations (69).
In patients with autosomal recessive congenital ichthyosis, IPS is
a rare condition, occurring in <4% of cases (70). Although they
are very similar conditions, there are some differences between
Netherton syndrome and IPS, mainly related with the skin
manifestations. Relevant to immunity, Netherton syndrome may
involve recurrent infections whereas IPS does not. This and the
immune defects initially reported by Professor H. Ochs indicate
that immunological laboratory tests are important to confirm or
rule out suspected Netherton syndrome.
DSG1—Erythroderma, Congenital, With Palmoplantar
Keratoderma, Hypotrichosis, and Hyper IgE (OMIM
#615508)
P16 is a female born of non-consanguineous Spanish parents
who, since the first 48 h of life, presented with erythrodermic
skin lesions co-occurring with bacterial infections, mainly skin
infections due to Staphylococcus aureus and sepsis caused
by S. epidermidis. The lesions increased in extension and
predominantly affected the distal limbs and the perioral and
periocular regions, causing uncontrollable itching. Laboratory
findings showed marked eosinophilia, reaching a value of
18% and 3.3 × 109 cells/L (normal range: 6–6.5%; 0–0.7
× 109/L). Immunoglobulin levels were normal except for
increased IgE (>2,000 KU/L). Immunophenotyping showed
an abnormal T cell phenotype, with a predominance of
memory/effector T cells. All these findings led to a differential
diagnosis that initially included hyper IgE syndrome (TYK2,
STAT3, DOCK8), Netherton syndrome (SPINK5), and Omenn
syndrome (RAG1, RAG2). Previous Sanger sequencing of
RAG1 and RAG2 showed no mutations, and the patient was
included in the CES project. The first analysis of sequencing
data (virtual PID panel) showed a heterozygous missense
variant in SPINK5 (c.2773G>C/p.Asp925His). This variant
was not reported in the main databases (dnSNP, ExAC,
gnomAD), and the computational predictions were discordant
(Supplementary Table 6). The variant was classified as a VUS,
and no other low-frequency variants were found in SPINK5.
Netherton syndrome is caused by biallelic mutations in SPINK5,
and all those reported are loss-of-function mutations (non-sense,
indels, and splicing mutations) (71). Therefore, the diagnosis
of Netherton syndrome was not supported by the genetic data.
A subsequent analysis revealed 2 heterozygous mutations in
DSG1: one was a start loss mutation (c.1A>G/p.Met1Val) and
the other a non-sense mutation (c.2569C>T/p.Arg857X). DSG1
encodes desmoglein 1, a major constituent of desmosomes,
which have a crucial role in maintaining epidermal integrity
and barrier function. Biallelic mutations in DSG1 cause SAM
(severe dermatitis, multiple allergies, and metabolic wasting)
syndrome (OMIM#615508) (72). Both mutations found in
our patient were private and her parents were heterozygous
carriers. SAM syndrome closely resembles Netherton syndrome,
including congenital ichthyosis, erythroderma, and severe atopic
dermatitis (73). As occurred in our patient and is reported in
Netherton syndrome, elevated serum IgE and absolute eosinophil
counts are found in DSG1-deficient patients (74–76). Other
laboratory immune defects have not been described to date. It
was recently demonstrated that DSG1 inhibits skin inflammation
by inhibiting the NF-kB signaling pathway (77). Consequently,
DSG1 deficiency is linked to inflammation and points to a crucial
link between loss of epithelial barrier integrity and immunologic
dysregulation (77).
DNAI2—Primary Ciliary Dyskinesia (OMIM #612444)
P17 is a 1-year old girl born of consanguineous parents. She had a
sister who died in the first year of life due to an unspecified heart
disease, and a 9-year-old brother with asthma, growth delay,
and multiple respiratory infections. At the age of 1 month, the
patient was referred to our hospital due to malignant pertussis.
During the following 3 months she experienced 4 episodes of
acute bronchitis, requiring 3 hospitalizations. At the age of 6
months she was admitted again to our hospital to study failure
to thrive. At 18 months of age, she developed biphenotypic
acute leukemia (i.e., acute leukemia with a single population
of blasts co-expressing markers of 2 different lineages), which
was treated with allogeneic cord blood hematopoietic stem
cell transplantation. PID was suspected based on the family
history, recurrent respiratory tract infections, and malignancy.
No pathogenic variants were found in the virtual PID panel, but
analysis of the other genes identified a homozygous non-sense
mutation in the DNAI2 gene (c.546C>A/p.Tyr182X). This gene
codes for the dynein axonemal intermediate chain 2 (DNAI2),
a protein belonging to the dynein intermediate chain family.
DNAI2 is highly expressed in trachea and testis and is involved
in the dynein regulatory complex of respiratory cilia and sperm
flagella motility (78). Biallelic mutations in DNAI2 have been
described as causing primary ciliary dyskinesia (PCD) (79).
PCD comprises a group of rare and genetically heterogeneous
disorders characterized by defective ciliary motility. PCD is
caused by biallelic mutations in more than 30 genes (the
number is rapidly increasing) related with the structure and
function of the cilia and flagella (80). Patients with these
disorders have a history of neonatal respiratory distress and
later, recurrent and chronic infections of the upper and lower
respiratory tracts that can lead to bronchiectasis and a progressive
decline in lung function. Other manifestations include organ
laterality defects (situs inversus), congenital heart disease, and
male infertility (81). As it can be seen, some clinical features of
PCD can overlap with other conditions, such as cystic fibrosis
and primary immunodeficiencies. Therefore, the differential
diagnosis between PCD and PID may be difficult, especially
in children. The non-sense homozygous mutation found in
DNAI2 perfectly explains the clinical phenotype of our patient.
Family study showed that the parents were heterozygous carriers
and the older brother was homozygous, in accordance with
his clinical symptoms (asthma, growth delay, and multiple
respiratory infections). It is likely that this mutation was the cause
of their sister’s early death due to a congenital heart disease.
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SIX6—Optic Disc Anomalies With Retinal and/or
Macular Dystrophy (OMIM #212550)
P18 is a 43-year old man born of consanguineous parents,
who presented with a dual phenotype showing both ocular
and immunological manifestations. The patient’s brother had
died at the age of 7 years due to complications related to
an immunodeficiency phenotype (more specific information
was not available). The pedigree revealed a high degree of
consanguinity in the family, and 2 cousins (a girl and a boy) had
the same ocular phenotype. The patient had congenital cataracts,
strabismus, and color blindness, although the most severe defect
was coloboma. He reported a history of multiple infections and
had a low platelet count and IgA deficiency. Despite normal
numbers of T, B and NK cells, the patient’s B cell subpopulations
were imbalanced, with increased numbers of naïve B cells and
reduced class-switch memory B cells. Immunodeficiency with
coloboma has been reported in CHARGE syndrome (82), but
our patient did not show most of the typical manifestations of
this syndrome (OMIM#214800). aCGH showed no abnormalities
and the patient was included in the CES study. Results of the
virtual PID panel analysis were negative, but in the subsequent
analysis, a rare homozygous variant was identified in the
SIX6 gene (c.86G>C/p.Arg29Pro). This variant had not been
previously described in general population. Biallelic mutations
in the SIX6 gene cause optic disc anomalies with retinal or
macular dystrophy (OMIM #212550), an autosomal recessive
condition characterized by iris coloboma, decreased or absent
vision, retinal dystrophy, and a colobomatous optic disc, among
other manifestations (83, 84). Segregation studies in the family
showed that both parents were heterozygous carriers of the
p.Arg29Pro mutation. However, functional studies should be
performed to confirm the pathogenicity of this variant. Since the
defects reported in patients with SIX6 deficiency are restricted
to ocular anomalies and 2 relatives have the ocular phenotype
but not the immunodeficiency, we conclude that our patient’s
immunological changes were caused by other genetic factors,
monogenic, oligogenic, or involving other more complex models
(as has been proposed in CVID and in selective IgA deficiency).
RECQL4—Rothmund-Thomson Syndrome (OMIM
#268400)
P19 is a 5-year old boy from a consanguineous Pakistani
family. At the age of 6 months, he experienced severe
diarrhea that lasted for 1 month. He had growth delay and
a polymalformative syndrome with skeletal malformations and
poikiloderma. He developed systemic cytomegalovirus infection
affecting the lung, and invasive aspergillosis that was difficult
to control. Laboratory data showed hypogammaglobulinemia,
lymphopenia, and thrombocytopenia. The CD4/CD8 ratio was
increased, with a predominance of memory cells within the CD8
compartment (59% of CD8+CD45RO+ T cells). The in vitro
lymphoproliferation capacity was impaired after stimulation
with pokeweed mitogen, anti-CD3 (also supplemented with IL-
2), or PHA. However, lymphoproliferation was normal with
PMA-ionomycin, thus indicating an upstream signaling defect.
Based on the patient’s syndromic features, the first genetic
test was aCGH, which showed no significant abnormalities.
The patient was then included in the CES study because
of suspected combined immunodeficiency (CID). None of
the genes responsible for CID included in the panel carried
pathogenic mutations. At that time, a diagnosis of Rothmund-
Thomson syndrome (RTS) was suggested by the clinical
geneticists and, indeed, a homozygous mutation was found in
the RECQL4 gene. It consisted of an in-frame deletion of 24
bp (c.2789_2812del), leading to the loss of 8 amino acids of the
protein (p.His930_Leu937del). This mutation, along with other
in-frame RECQL4 deletions/duplications, have been described as
pathogenic and a cause of RTS (85). RTS is an autosomal recessive
genodermatosis presenting in infancy with a characteristic facial
rash (poikiloderma) and other manifestations, including short
stature, skeletal abnormalities, ocular defects, premature aging,
and a predisposition to cancer (86). Although immune defects
are not among the classical features of this syndrome, a few RTS
patients with immunological abnormalities have been reported.
In the 1990s, 2 RTS patients with humoral immune deficiencies
(involving hypogammaglobulinemia) were described (87, 88).
In 2006, Broom et al. described a patient with CID and a
classic RTS phenotype who experienced successful immune
reconstitution following umbilical cord blood transplantation
(89). Later, in 2010, De Somer at al presented a patient with
RTS and immune deficiency who developed granulomatous skin
lesions after primary varicella-zoster virus infection (90). In a
more recent study, Smeets et al. shed light on the question of
why mutations in RECQL4 can lead to these immunological
abnormalities. These authors found that Recql4 loss causes rapid
bone marrow failure in mice, leading to profound disruption
of immune development, including impaired B and T cell
development (91).
Collectively, these data suggest a role of the DNA helicase
RECQL4 in the development of the immune system, and indicate
that screening for immune deficiency should be considered in
patients with RTS.
Incomplete Genotypes and Variants of
Uncertain Significance
An inherent feature of NGS is generation of large amounts of data
and identification of a myriad of genetic variants. The clinical
significance of a variable fraction of these variants may be difficult
to ascertain based on current knowledge; thus, they are referred
to as variants of uncertain/unknown significance (VUS).
In all patients undergoing CES in this study and excluding the
causal mutations described above (Table 4), we found a varying
number of low-frequency (MAF>0.01) variants in the virtual
PID panel, considered not to be a cause of the clinical phenotype
(Supplementary Table 6, which does not include variants in
Table 4). Most of these variants are rare polymorphisms with
no clear functional impact, but others are monoallelic loss-of-
function variants in recessive genes that are clearly unrelated to
the patients’ disease. Nonetheless, a potential role of some of
these variants as modulators of the clinical phenotype cannot
be excluded.
A few of these variants, located in genes related to the patients’
phenotypes, drew our attention (Table 4).
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A heterozygous missense variant in UNC13D (p.Arg1075Gln)
was identified in P20, who presented with pancytopenia,
hepatosplenomegaly, hemophagocytosis, and subcutaneous
panniculitis-like T cell lymphoma at the age of 8 years. Elevated
HLH biomarkers and absent cytotoxicity and degranulation
supported the diagnosis of fHLH. However, the functional tests
normalized after the episode. The role of monoallelic variants in
HLH is currently a topic of great interest and debate (92). We
also sequenced UNC13D intron 1 by Sanger because pathogenic
mutations have been reported in several HLH patients with
monoallelic mutations in the coding regions (93–95), but
no relevant variants were found. The role of the UNC13D
p.Arg1075Gln variant is under study.
P21 is a male with failure to thrive and a family
history of a sister who died at the age of 6 months due
to unknown reasons. The patient had a clinical phenotype
of multiple lymphadenopathies, intermittent abdominal pain,
persistent fever, and granulomatous hepatitis. Analyses showed
lymphopenia and low platelet counts. We found a heterozygous
missense variant at very low frequency in the RAG2 gene
(p.Ala442Thr), classified as likely pathogenic following the
ACMG rules (96). The clinical phenotype of the patient fits well
with those observed in some patients with biallelic RAG1 or
RAG2mutations (97), but in this case we found only 1 mutation.
P22 presented with recurrent fevers seriously affecting his
quality of life, with no response to colchicine or IL-1 inhibitors.
Since the age of 6 years, he has also experienced episodes of
sudden loss of muscle tone and consciousness. We identified a
heterozygous missense variant in the PLCG2 gene (p.Asn798Ser),
predicted to be pathogenic by SIFT and PolyPhen2. The
prevalence of this variant population is low (but not very low),
and it was inherited from his mother.
In P23, a girl with herpes simplex encephalitis, we found a low-
frequency heterozygousmissense variant inTRAF3 (p.Val240Ile).
TRAF3 deficiency (autosomal dominant) has been associated
with a clinical phenotype limited to herpes simplex encephalitis
resulting from impairment of the TLR3 response. Only 1 patient
with this condition has been reported (98). Our variant shows
a low frequency in the general population, SIFT and PolyPhen2
classified it as benign, and it was inherited from the patient’s
mother. DNA-sensing pathway responsiveness is under study to
evaluate the functional impact of this TRAF3 variant.
P24 presented with early-onset inflammatory bowel disease at
the age of 7 months, together with hypogammaglobulinemia. We
identified a low-frequency missense variant in the NOD2 gene
(p.Ala918Asp). NOD2 variants have been repeatedly associated
with Crohn’s disease (99), and p.Ala918Asp is among the ones
most strongly associated (38). It seems clear that this variant is
not the cause of the full clinical phenotype of P24, but it may play
a role in the patient’s gastrointestinal manifestations.
Genetic Findings Post-clinical Exome in
Patients With Negative Results
Typically, patients with negative results on genetic testing
remain as “genetically undiagnosed,” and if suspicion of a
genetic defect persists, they are usually included in other
genetic testing approaches over time. During the 3 years of
this study, most patients with negative CES results have been
analyzed by other methods, and some of them ultimately
received a genetic diagnosis. In P25, P26, and P27, clinically
diagnosed as having CVID, biallelic mutations were identified
in the LRBA gene. In 2012, LRBA deficiency was described
as a monogenic cause of CVID associated with autoimmunity
(100). LRBA is not included in the TruSight One Sequencing
Panel, likely because it was discovered as a cause of CVID
after the panel was designed (Illumina announced launch of
the TSO panel in October 2013). This is one of the main
limitations of CES: it can lack relevant genes described after
it was designed. Samples from P26 and P27 were included in
a targeted panel of CVID genes and P25 underwent WES. Of
note, in P25, we reported the first case of LRBA deficiency due
to uniparental disomy (101). A similar situation occurred in
P28, clinically diagnosed as having CVID, but later tested with
a more specific PID panel, which detected a heterozygous loss-
of-function mutation in IKZF1. Monoallelic mutations in IKZF1
(encoding IKAROS) were described as a monogenic cause of
CVID in 2016 (102), but earlier, in 2012, a single patient with
IKZF1 mutation was reported to have congenital pancytopenia
(103). This gene is also absent from the TSO. P29 is a
patient with autoinflammatory manifestations, and additionally,
psychomotor and growth delay. Following CES, we performed
aCGH, which revealed a deletion of 13Mb on chromosome 6
including the TNFAIP3 gene. TNFAIP3 haploinsufficiency causes
an autoinflammatory syndrome (Behcet-like) (104), which in our
patient occurred together with other developmental impairments
due to this large deletion (105). CES does not perform well for
detecting large genomic rearrangements and, indeed, this defect
was not detected in the CES data analysis. P30, with a strong
clinical suspicion of X-linked agammaglobulinemia (XLA), was
included in CES because we found no mutations in BTK by
direct sequencing. CES was also negative. Since suspicion of XLA
persisted, we performed western blot analysis of the BTK protein,
which revealed an absence of BTK. Finally, a large deletion
affecting the BTK 5′UTR was identified. As CES is focused
on the coding regions, it was unable to detect this deletion.
This limitation is inherent to all the approaches based on
sequencing only the coding regions (usually targeted gene panels
and WES) and can only be overcome by using WGS (or other
specific techniques to detect CNVs). Finally P31 presented with
monostotic fibrous dysplasia of the lumbar spine and episodes
of bacterial infections with a complicated course. After CES had
yielded negative results, we performed aCGH, which provided
no relevant findings. Ultimately, the patient was diagnosed with
Gorham-Stout Disease (GSD), a rare disorder characterized by
angiogenesis, lymphangiomatosis, and severe bone resorption
(106). The exact cause of GSD is unknown and no environmental,
immunological or genetic risk factors have been identified.
Bone loss in GSD is accompanied by uncontrolled growth
(proliferation) of lymphatic tissue. Lymphatic abnormalities
could be related to the recurrent infections in P31.
CONCLUDING REMARKS
In this study, CES was used to analyze samples from 61
patients with clinically suspected PID. Aside from detection
of mutations in genes typically causing PID, CES enabled
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molecular identification of defects in genes that are not present
in the IUIS classification or in specific PID panels, as well
as identification of unsuspected molecular etiologies. These
findings indicate that some cases of clinically suspected PID
may ultimately not correspond to a “genuine” PID, as a number
of rare diseases include immune-related symptoms in their
typical or atypical presentations. Furthermore, they illustrate
one of the advantages of CES over the use of more specific
PID panels. In contrast, the main limitation of CES for genetic
diagnosis of PIDs is the lack of a considerable number of
PID-causing genes. There is a simple reason for this: most
of the absent genes were discovered after the clinical exome
panel was designed. Typically, clinical exome panels provided by
companies are not easily customized. In contrast, specific tailor-
made PID panels can be periodically updated and may be more
comprehensive in terms of PID-causing genes. Nonetheless,WES
is becoming the gold-standard technique for the diagnosis of
genetic diseases, and it is replacing CES as an unbiased approach
covering all coding regions of the genome. However, despite
continuing decreases in the cost of this technique, it remains
expensive and the data analysis is difficult to manage for some
centers. Hence, CES may still be a good practical option for
this purpose.
Overall, we obtained a positive genetic finding in 42%
of patients including CES approach and the other diagnoses
achieved by later use of other techniques. Several reasons may
explain the lack of genetic diagnosis in 58% of patients; the most
intuitive one is the limited number of genes included in CES.
Probably the use of WES and WGS would increase diagnostic
rate but still a percentage of patients would remain undiagnosed.
Very recently, Yska and collaborators systematically reviewed
the diagnostic yield of NGS in genetically undiagnosed patients
with PIDs and they found a broad range among the different
studies (15–79%) (107). Several factors may explain this
high variability, including methodological differences and the
selected study populations. Other biological reasons like the
existence of complex models of inheritance (e.g., oligogenic,
polygenic, epigenetic) may difficult to achieve a definitive
genetic diagnosis.
The number of VUS obtained in CES, WES and especially in
WGS is also a challenging aspect inherent of NGS approaches.
The ACMG guidelines suggest the management of VUS
as follows: “A variant of uncertain significance should not
be used in clinical decision making. Efforts to resolve the
classification of the variant as pathogenic or benign should
be undertaken. While this effort to reclassify the variant is
underway, additional monitoring of the patient for the disorder
in question may be prudent” (96). However, how to deal with
VUS in a clinical setting is a continuous matter of debate (108,
109).
In summary, this study describes our experience in using
CES as a tool for the genetic diagnosis of PIDs and discusses
the expected and unexpected findings obtained. We believe
it is of clinical interest to provide descriptions of patients
with mutations in genes that are not included in the PID
classification to aid in the differential diagnosis of some suspected
PIDs. The cases described illustrate the heterogeneity and
complexity encountered by professionals involved in the clinical
management and genetic diagnosis of these disorders.
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